Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2012-04-11 AGM Information
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
BR-#6772473-v1-Thrombogenics_-_Omschrijving_vraagrecht_recht_agendapunten_toe_te_voegen_-_EN.PDF
AGM Information Classification · 98% confidence The document explicitly discusses the rights of shareholders regarding the agenda, proposals for decision, and asking questions in writing for a general meeting scheduled for '2 May 2012'. Key phrases include 'GENERAL MEETING', 'AGENDA ITEMS', 'PROPOSALS FOR DECISION', and 'VOTING RIGHTS'. This content is directly related to the procedures and materials governing an Annual General Meeting (AGM). While it details shareholder rights which might overlap with Proxy Solicitation (PSI), the focus on adding agenda items and general meeting procedures strongly points to AGM-related documentation, likely a notice or circular leading up to the meeting. Given the options, AGM-R (AGM Information) is the most appropriate fit for materials detailing shareholder rights concerning the AGM agenda and proceedings.
2012-04-11 English
BR-#6772470-v1-Thrombogenics_-_Omschrijving_vraagrecht_recht_agendapunten_toe_te_voegen_-_NL.PDF
Proxy Solicitation & Information Statement Classification · 98% confidence The document text is titled 'ACHTERGRONDINFORMATIE OVER DE RECHTEN VAN DE AANDEELHOUDERS OVEREENKOMSTIG DE ARTIKELEN 533ter et 540 VAN HET WETBOEK VAN VENNOOTSCHAPPEN' (Background information on the rights of shareholders according to Articles 533ter and 540 of the Companies Code). It details the procedures and deadlines for shareholders to submit topics for the agenda, submit draft resolutions, and ask written questions ahead of a General Meeting scheduled for May 2, 2012. This content is directly related to the preparation and conduct of a shareholder meeting, specifically concerning proxy voting, agenda setting, and shareholder rights prior to the vote. This strongly aligns with the purpose of a Proxy Solicitation & Information Statement (DEF 14A or PSI). Since the document focuses heavily on the rights to submit proposals and ask questions leading up to the meeting, and mentions proxy forms, it fits the definition of Proxy Solicitation & Information Statement (PSI) better than the general AGM-R (which usually covers the actual meeting materials/presentations). It is not the final voting results (DVA), nor is it the full annual report (10-K). Given the focus on shareholder rights regarding the agenda and voting procedures, PSI is the most appropriate classification.
2012-04-11 Dutch
ThromboGenics_Warrantplan_2013_Verslag583 (2).pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled 'BUZONDER VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG ARTIKEL 583 VAN HET WETBOEK VAN VENNOOTSCHAPPEN' (Special Report of the Board of Directors pursuant to Article 583 of the Companies Act). The content explicitly details the proposed issuance of 720,000 warrants ('warranten') to key personnel and employees as part of a new 'Warrantenplan 2013' (Warrant Plan 2013). This involves changes to the capital structure (issuance of options/warrants) requiring board and shareholder approval, which is typical for financing or capital structure documents. Since the document focuses on the proposal and terms for issuing capital instruments (warrants) rather than a general financial report (10-K, IR) or a simple announcement of a transaction (POS, SHA), the most fitting category is 'Capital/Financing Update' (CAP). It is a detailed report justifying a capital action.
2012-04-10 Dutch
ThromboGenics_WarrantPlan_2013_VolmachtBAV (4).pdf
AGM Information Classification · 98% confidence The document is explicitly titled 'VOLMACHT' (Proxy) and contains instructions for a shareholder to appoint a representative for a 'buitengewone algemene vergadering' (extraordinary general shareholders' meeting). It details the agenda for this meeting, which includes proposals related to a new warrant plan and capital structure changes. This form is used to grant voting authority for a general meeting, which is a core component of shareholder communication related to corporate governance and meeting procedures. While it relates to matters often discussed at an AGM, the document itself is the proxy form used to delegate voting rights for that meeting. The closest fit among the provided codes is 'AGM-R' (AGM Information), as proxy forms are integral materials distributed in connection with Annual/Extraordinary General Meetings. It is not the minutes, the results (DVA), or the main report (10-K/IR). Given the context of granting representation for a general meeting, AGM-R is the most appropriate classification.
2012-04-10 Dutch
ThromboGenics_WarrantPlan_2013_VerslagCommissaris (2).pdf
Capital/Financing Update Classification · 95% confidence The document is a formal report addressed to the shareholders of THROMBOGENICS NV. It is titled 'Verslag van de commissaris betreffende de opheffing van het voorkeurrecht van bestaande aandeelhouders overeenkomstig artikelen 596 en 598 van het Wetboek van vennootschappen' (Commissioner's Report regarding the cancellation of the pre-emptive rights of existing shareholders pursuant to articles 596 and 598 of the Companies Code). It also includes the 'BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG DE ARTIKELEN 596 EN 598 VAN HET WETBOEK VAN VENNOOTSCHAPPEN' (Special Report of the Board of Directors pursuant to Articles 596 and 598 of the Companies Code). These articles specifically deal with the procedures and required reports when a company proposes to cancel pre-emptive rights (voorkeurrecht) during a capital increase or issuance of warrants, which is a financing/capital structure activity. While it involves capital structure changes (CAP) and is a formal report (AR/IR), the core function described by the specific legal articles (596 and 598) and the content (the Commissioner's verification of the Board's report regarding the cancellation of pre-emptive rights for a warrant issuance) strongly aligns with documents related to financing activities and capital structure adjustments. However, none of the provided codes perfectly match a 'Report on Cancellation of Pre-emptive Rights'. We must choose the closest fit: - CAP (Capital/Financing Update): This covers fundraising and capital structure changes. The document is the formal report supporting such a change (issuance of warrants/capital increase). - AR (Audit Report / Information): This is a standalone audit report or stress test result. This document is a specific statutory report required for a corporate action, not a general audit report. - LTR (Legal Proceedings Report): Incorrect. Given the context of issuing warrants and capital increase, CAP is a strong candidate. However, the document is a formal, detailed statutory report required by law for a specific corporate action (cancellation of pre-emptive rights related to a capital increase/warrant issuance). In many filing systems, detailed statutory reports supporting major corporate actions like this are often classified under a general 'Statutory Report' or sometimes grouped with 'Audit Reports' if the commissioner's role is central, or under 'Capital/Financing Update' if the focus is the transaction itself. Considering the document is a formal, detailed report (28k chars) verifying the fairness of financial data related to a capital increase/warrant issuance, it is more than just an 'Update' (CAP). It is a formal statutory report required for the transaction. Since it is a detailed report verifying financial data related to a corporate action, and not a general annual/interim report, 'Audit Report / Information' (AR) is often used for specific statutory verification reports by the auditor/commissioner, even if not a full financial audit. Let's re-evaluate the definitions: - AR: Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports). - CAP: Updates on company fundraising, financing activities, or capital structure changes. The document is a 'Commissioner's Report' verifying the Board's report concerning the cancellation of pre-emptive rights for a warrant issuance. This is a highly specific statutory report required for a financing activity. Since the document is a formal, detailed report (not a short announcement) and involves the statutory verification by the commissioner, AR is a plausible fit for a specific statutory verification report. However, the *subject matter* is purely financing/capital structure. If we prioritize the *subject matter* (issuance of warrants/capital increase), CAP is best. If we prioritize the *nature* (a formal statutory report by the commissioner), AR is plausible. In the context of Belgian corporate law documents concerning capital structure changes requiring auditor verification (Articles 596/598), this is fundamentally a report supporting a financing event. Therefore, CAP (Capital/Financing Update) is the most appropriate category for the underlying economic event being reported on, even though the document itself is a formal statutory report. *Self-Correction/Refinement*: The document is a formal, detailed statutory report required by law (Articles 596/598) to enable a capital increase via warrant issuance. This is a core financing activity. While it is a report, it is not a general financial report (10-K, IR). It is a report *about* a financing activity. I will classify it as CAP, as it details the justification for cancelling pre-emptive rights for a warrant issuance, which is a financing activity.
2012-04-10 Dutch
ThromboGenics_WarrantPlan_2013_Verslag598 (2).pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "BUZONDER VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG BE ARTIKELEN 596 EN 598 VAN HET WETBOEK VAN VENNOOTSCHAPPEN" (Special Report of the Board of Directors pursuant to Articles 596 and 598 of the Companies Act). This structure, detailing a proposal (issuance of warrants and capital increase) and explaining the financial consequences for existing shareholders, is characteristic of a formal report prepared for a shareholder meeting, specifically an Extraordinary General Meeting (EGM) as mentioned in the text ("buitengewone algemene vergadering"). This type of document, which provides detailed justification for a significant corporate action (like issuing shares/warrants, often involving waiving pre-emptive rights), aligns best with a document related to capital structure changes or governance disclosures presented to shareholders. Since it is a detailed report justifying a capital action (warrant issuance and capital increase) and is presented to shareholders for a vote, it strongly suggests a document related to Capital/Financing Update (CAP) or potentially a specialized governance/shareholder document. Given the focus on the proposal to waive preference rights for a warrant issuance and the detailed financial impact analysis, 'Capital/Financing Update' (CAP) is the most fitting primary category, as it directly concerns a capital structure change. It is not a standard 10-K, ER, or IR. It is a formal report, not just an announcement of a report (RPA/RNS).
2012-04-10 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.